WIRE)–According to Millennium Research Group (MRG), the global authority
on medical technology market intelligence, strong growth in the United States
peripheral vascular (PV) market will come in lower-extremity indications,
particularly through the adoption of drug-eluting stents (DES), which will be
introduced into the US market in 2012.
DES has shown success in coronary indications, which has
encouraged the development of DES products for peripheral vessels as well.
While growing in popularity in Europe, peripheral versions of DES have not been
available in the United
States. Cook Medicals Zilver PTX is
expected to receive Food and Drug Administration (FDA) approval early in 2012.
DES will mostly be used initially in femoropopliteal (fem-pop) indications,
with use also in the infropopliteal in 2015 and beyond. The overall fem-pop
segment had a value of $290 million in 2011 and is expected to reach over $460
million by 2016, a growth rate that averages nearly 10 percent per year.
Drug-eluting stents are expected to address some of the
concerns with current stents used in lower-extremity indications, which include
restenosis, high rates of re-intervention and durability concerns. The results
should be better outcomes in safety and efficacy. As a result, DES in the
fem-pop segment should reach 30,000 procedures per year by 2016, making up
nearly 7.5 percent of all fem-pop stenting procedures.
“DES is promising, but improvements are constantly being
made to its competitors, primarily bare-metal stents, but also including
covered stents,” said MRG Analyst Fareed Hameed. “Flexible Stenting Solutions
and IDEV technologies have new bare-metal designs, while W. L. Gore and Atrium
Medical both have made continuous improvements to their covered stents.
Physicians need to learn new procedures to use any of these designs
effectively, which does decrease the speed of adoption.”
Millennium Research Groups US Markets for Peripheral
Vascular Devices 2012 report includes procedure, unit, average selling price
and revenue information, along with market drivers and limiters and competitive
landscape for PV stents, PTA balloon catheters, atherectomy devices, EPDs,
aortic stent grafts, synthetic and biologic surgical stent grafts and PV
accessory devices sold in the United
About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on
medical technology market intelligence and the leading provider of strategic
information to the healthcare sector. The company provides specialized industry
expertise through multiclient market research, ongoing Marketrack™ projects,
customer loyalty tracking, facility-level procedure forecasting, and customized
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information, and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
Posted by Sean Fenske, Editor-in-Chief, MDT